NASDAQ:TCDATricida Stock Price, Forecast & News

Tricida's stock was trading at $28.05 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TCDA shares have decreased by 52.6% and is now trading at $13.30.
View which stocks have been most impacted by COVID-19.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Tricida.

Tricida is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Tricida.

Tricida Inc (NASDAQ:TCDA) issued its quarterly earnings data on Wednesday, August, 5th. The company reported ($1.16) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($1.46) by $0.30.
View Tricida's earnings history.

2 equities research analysts have issued 12-month price targets for Tricida's stock. Their forecasts range from $40.00 to $44.00. On average, they anticipate Tricida's stock price to reach $42.00 in the next year. This suggests a possible upside of 215.8% from the stock's current price.
View analysts' price targets for Tricida.

Media coverage about TCDA stock has trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Tricida earned a media sentiment score of -1.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future.
View the latest news about Tricida.

Some companies that are related to Tricida include Pacira Biosciences (PCRX), Taro Pharmaceutical Industries (TARO), Karuna Therapeutics (KRTX), Turning Point Therapeutics (TPTX), Apellis Pharmaceuticals (APLS), TG Therapeutics (TGTX), Prestige Consumer Healthcare (PBH), Xencor (XNCR), Uniqure (QURE), Ligand Pharmaceuticals (LGND), Aurinia Pharmaceuticals (AUPH), Intercept Pharmaceuticals (ICPT), IGM Biosciences (IGMS), I-Mab (IMAB) and Eidos Therapeutics (EIDX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Gilead Sciences (GILD), Myovant Sciences (MYOV), VBI Vaccines (VBIV), Atara Biotherapeutics (ATRA), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), Pfizer (PFE), AbbVie (ABBV), Agile Therapeutics (AGRX) and Biohaven Pharmaceutical (BHVN).

(TCDA) raised $175 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen acted as the underwriters for the IPO.

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Tricida's stock is owned by a number of retail and institutional investors. Top institutional investors include New York State Common Retirement Fund (0.46%), Candriam Luxembourg S.C.A. (0.38%), Bank of New York Mellon Corp (0.23%), Barclays PLC (0.14%), Swiss National Bank (0.13%) and UBS Group AG (0.12%). Company insiders that own Tricida stock include Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Geoffrey M Parker, Gerrit Klaerner, Klaus R Dr Veitinger, Orbimed Advisors Llc, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP and Wilhelm Stahl.
View institutional ownership trends for Tricida.

TCDA stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., and California Public Employees Retirement System. Company insiders that have sold Tricida company stock in the last year include Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Gerrit Klaerner, Klaus R Dr Veitinger, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP, and Wilhelm Stahl.
View insider buying and selling activity for Tricida.

TCDA stock was purchased by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, SG Americas Securities LLC, Barclays PLC, Russell Investments Group Ltd., Swiss National Bank, Aigen Investment Management LP, Bank of New York Mellon Corp, and Trexquant Investment LP. Company insiders that have bought Tricida stock in the last two years include Geoffrey M Parker, and Orbimed Advisors Llc.
View insider buying and selling activity for Tricida.

Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TCDA stock can currently be purchased for approximately $13.30.

Tricida has a market capitalization of $665.65 million. The company earns $-176,810,000.00 in net income (profit) each year or ($3.72) on an earnings per share basis. Tricida employs 76 workers across the globe.

The official website for Tricida is www.tricida.com.

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]